The E-LIFT trial involving patients with T2DM and NAFLD, demonstrated that empagliflozin, in addition to standard diabetes management, causes a significant reduction in liver fat content (as measured by magnetic resonance imagingestimated proton density fat fraction) and alanine aminotransferase level, and a non-significant reduction in gamma-glutamyl transferase and aspartate aminotransferase levels [71,72,73]
Probiotics show mixed evidence for GLP-1-related diarrhea
Lipo-C with B Vitamins Treatment Protocol Lipo-C with B vitamins has emerged as a promising intervention for managing Retatrutide allodynia in research settings
If nausea, vomiting, or diarrhea remain significant at any dose, hold that dose for an additional two to four weeks before escalating
The GLP-1 Companion also provides personalized guidance for those on GLP-1 medications
10.1016/j.ajem.2023.07.020 102 RyanP